New hybrid bromopyridine-chalcones as in vivo phase II enzyme inducers: potential chemopreventive agents
作者:Mauricio Cabrera、Hugo Cerecetto、Mercedes González
DOI:10.1039/c6md00456c
日期:——
administration of cancer chemopreventive agents (CCAs) that prevent, delay or reverse the carcinogenic process. CCAs that are able to induce detoxification enzymes, especially monofunctional phase II enzymes, have become an excellent therapeutic strategy. Herein, we report the synthesis of eighteen new potential CCAs, structurally designed to combine (naphtho)chalcone and (bromo)pyridine skeletons. After a selection
预防癌症可以通过施用预防,延迟或逆转致癌过程的癌症化学预防剂(CCA)来实现。能够诱导解毒酶,尤其是单功能II期酶的CCA已成为一种出色的治疗策略。在这里,我们报告了十八种新的潜在CCA的合成,其结构设计为结合(萘)查耳酮和(溴)吡啶骨架。经过涉及体外II期诱导研究的选择过程,针对肿瘤细胞的细胞毒性,诱变性(Ames试验)和DNA链断裂能力(碱性彗星试验),化合物22,(E)-3-(2-溴吡啶啶)选择了-3-基)-1-(2-羟基苯基)-2-丙烯-1-酮进行动物研究。这衍生物22的体内概念研究证明,它能够显着增加肝脏,结肠和乳腺的QR和GST活性,而不会显着诱导I期酶CYP。此外,我们发现,对于22种和另一种体外QR活性诱导剂,(E)-1-(2-羟苯基)-3-(萘-1-基)-2-丙烯-1-酮(化合物8)Nrf2核易位有效,可通过下游II期酶的表达发挥保护作用。